Drug treatment discontinuation and achievement of target blood pressure and cholesterol in United Kingdom primary care

References

• Wong ND, Pio JR, Franklin SS, et al. Preventing coronary events by optimal control of blood pressure and lipids in patients with the metabolic syndrome. Am J Cardiol 2003;91:1421–6
   PubMed Web of Science ®Google Scholar
• Wald NJ, Law MR. A strategy to reduce cardiovascular disease by more than 80%. BMJ 2003;326:1419
   PubMed Web of Science ®Google Scholar
• Cowie MR. Simultaneous treatment of hypertension and dyslipidaemia may help to reduce overall cardiovascular risk: focus on amlodipine/atorvastatin single-pill therapy. Int J Clin Pract 2005;59:839–46
   PubMed Web of Science ®Google Scholar
• Wuerzner K, Hassler C, Burnier M. Difficult blood pressure control: watch out for non-compliance! Nephrol Dial Transplant 2003;18:1969–73
   PubMed Web of Science ®Google Scholar
• Wolf-Maier K, Cooper RS, Kramer H, et al. Hypertension treatment and control in five European countries, Canada, and the United States. Hypertension 2004;43: 10–7
   Google Scholar
• Johnson ML, Pietz K, Battleman DS, et al. Therapeutic goal attainment in patients with hypertension and dyslipidemia. Med Care 2006;44:39–46
   PubMed Web of Science ®Google Scholar
• Wong ND, Lopez V, Tang S, et al. Prevalence, treatment, and control of combined hypertension and hypercholesterolemia in the United States. Am J Cardiol 2006;98:204–8
   PubMed Web of Science ®Google Scholar
• Pearson TA, Laurora I, Chu H, et al. The lipid treatment assessment project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals. Arch Intern Med 2000;160:459–67
   PubMed Web of Science ®Google Scholar
• Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries; principal results from EUROASPIRE II Euro Heart Survey Programme. Eur Heart J 2001;22:554–72
   PubMed Web of Science ®Google Scholar
• Primatesta P, Poulter NR. Lipid levels and the use of lipid-lowering agents in England and Scotland. Eur J Cardiovasc Prev Rehabil 2004;11:484–8
   PubMed Web of Science ®Google Scholar
• Primatesta P, Poulter NR. Levels of dyslipidaemia and improvement in its management in England: results from the Health Survey for England 2003. Clin Endocrinol (Oxf) 2006;64:292–8
   PubMed Web of Science ®Google Scholar
• Braunstein JB, Cheng A, Cohn G, et al. Lipid disorders: justification of methods and goals of treatment. Chest 2001;120: 979–88
   Google Scholar
• Tarn DM, Heritage J, Paterniti DA, et al. Physician communication when prescribing new medications. Arch Intern Med 2006;166:1855–62
   PubMed Web of Science ®Google Scholar
• O’Connor PJ. Improving medication adherence: challenges for physicians, payers, and policy makers. Arch Intern Med 2006;166:1802–4
   PubMed Web of Science ®Google Scholar
• Lipsy RJ. Effective management of patients with dyslipidemia. Am J Manag Care 2003;9:S39–58
   Google Scholar
• Wei L, Wang J, Thompson P, et al. Adherence to statin treatment and readmission of patients after myocardial infarction: a six year follow up study. Heart 2002;88:229–33
   PubMed Web of Science ®Google Scholar
• Ho PM, Spertus JA, Masoudi FA, et al. Impact of medication therapy discontinuation on mortality after myocardial infarction. Arch Intern Med 2006;166:1842–7
   PubMed Web of Science ®Google Scholar
• Ho PM, Rumsfeld JS, Masoudi FA, et al. Effect of medication nonadherence on hospitalization and mortality among patients with diabetes mellitus. Arch Intern Med 2006;166:1836–41
   PubMed Web of Science ®Google Scholar
• Garcia Rodriguez LA, Perez Gutthann S. Use of the UK General Practice Research Database for pharmacoepidemiology. Br J Clin Pharmacol 1998;45:419–25
   PubMed Web of Science ®Google Scholar
• Jick H, Jick SS, Derby LE. Validation of information recorded on general practitioner based computerised data resource in the United Kingdom. BMJ 1991;302:766–8
   Google Scholar
• Lawrenson R, Todd JC, Leydon GM, et al. Validation of the diagnosis of venous thromboembolism in general practice database studies. Br J Clin Pharmacol 2000;49:591–6
   PubMed Web of Science ®Google Scholar
• Soriano JB, Maier WC, Visick G, et al. Validation of general practitioner-diagnosed COPD in the UK General Practice Research Database. Eur J Epidemiol 2001;17:1075–80
   PubMed Web of Science ®Google Scholar
• Lewis JD, Brensinger C, Bilker WB, et al. Validity and completeness of the General Practice Research Database for studies of inflammatory bowel disease. Pharmacoepidemiol Drug Saf 2002;11:211–8
   PubMed Web of Science ®Google Scholar
• Lewis JD, Brensinger C. Agreement between GPRD smoking data: a survey of general practitioners and a population-based survey. Pharmacoepidemiol Drug Saf 2004;13:437–41
   PubMed Web of Science ®Google Scholar
• Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987;40:373–83
   PubMedGoogle Scholar
• 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003;21: 1011–53
   Google Scholar
• Wood D, De Backer G, Faergeman O, et al. Prevention of coronary heart disease in clinical practice: recommendations of the Second Joint Task Force of European and other Societies on Coronary Prevention. Atherosclerosis 1998;140:199–270
   PubMed Web of Science ®Google Scholar
• Burke TA, Sturkenboom MC, Lu SE, et al. Discontinuation of antihypertensive drugs among newly diagnosed hypertensive patients in UK general practice. J Hypertens 2006;24:1193–200
   PubMed Web of Science ®Google Scholar
• Chapman RH, Benner JS, Petrilla AA, et al. Predictors of adherence with antihypertensive and lipid-lowering therapy. Arch Intern Med 2005;165:1147–52
   PubMed Web of Science ®Google Scholar
• Blackburn DF, Dobson RT, Blackburn JL, et al. Adherence to statins, beta-blockers and angiotensin-converting enzyme inhibitors following a first cardiovascular event: a retrospective cohort study. Can J Cardiol 2005;21:485–8
   PubMed Web of Science ®Google Scholar
• Neaton JD,Wentworth D. Serum cholesterol, blood pressure, cigarette smoking, and death from coronary heart disease. Overall findings and differences by age for 316,099 white men. Multiple Risk Factor Intervention Trial Research Group. Arch Intern Med 1992;152: 56–64
   Google Scholar
• Poulter N. Coronary heart disease is a multifactorial disease. Am J Hypertens 1999;12:92S–95S
   Google Scholar
• Tunstall-Pedoe H. What was preventing coronary heart disease (CHD) prevention and why its time has now come. In Wood, D, McLeod, A, Davis, M, Miles, A (eds): Effective Secondary Prevention and Cardiac Rehabilitation. London: Aesculapius Press, 2002:3–13
   Google Scholar
• Thomas F, Bean K, Guize L, et al. Combined effects of systolic blood pressure and serum cholesterol on cardiovascular mortality in young (< 55 years) men and women. Eur Heart J 2002;23:528–35
   PubMed Web of Science ®Google Scholar
• Clinical reality of coronary prevention guidelines: a comparison of EUROASPIRE I and II in nine countries. EUROASPIRE I and II Group. European Action on Secondary Prevention by Intervention to Reduce Events. Lancet 2001;357: 995–1001
   Google Scholar
• Mantel-Teeuwisse AK, Klungel OH, Verschuren WM, et al. Time trends in lipid lowering drug use in The Netherlands. Has the backlog of candidates for treatment been eliminated? Br J Clin Pharmacol 2002;53:379–85
   Google Scholar
• Hajjar I, Kotchen TA. Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988–2000. JAMA 2003;290: 199–206
   Google Scholar
• Ford ES, Mokdad AH, Giles WH, et al. Serum total cholesterol concentrations and awareness, treatment, and control of hypercholesterolemia among US adults: findings from the National Health and Nutrition Examination Survey, 1999 to 2000. Circulation 2003;107:2185–9
   PubMed Web of Science ®Google Scholar
• van Wyk JT, Picelli G, Dieleman JP, et al. Management of hypertension and hypercholesterolaemia in primary care in the Netherlands. Curr Med Res Opin 2005;21:839–48
   PubMed Web of Science ®Google Scholar
• Wright DJ, Grayson AD, Jackson M, et al. The reality of treating dyslipidaemia in patients with coronary heart disease: a primary care survey. Int J Clin Pract 2003;57:488–91
   PubMed Web of Science ®Google Scholar
• Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003;42:1206–52
   PubMed Web of Science ®Google Scholar
• Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001;285: 2486–97
   Google Scholar
• Jones JK, Gorkin L, Lian JF, et al. Discontinuation of and changes in treatment after start of new courses of antihypertensive drugs: a study of a United Kingdom population. BMJ 1995;311:293–5
   PubMed Web of Science ®Google Scholar
• Monane M, Bohn RL, Gurwitz JH, et al. The effects of initial drug choice and comorbidity on antihypertensive therapy compliance: results from a population-based study in the elderly. Am J Hypertens 1997;10:697–704
   PubMed Web of Science ®Google Scholar
• Avorn J, Monette J, Lacour A, et al. Persistence of use of lipid-lowering medications: a cross-national study. JAMA 1998;279:1458–62
   PubMed Web of Science ®Google Scholar
• McDonald HP, Garg AX, Haynes RB. Interventions to enhance patient adherence to medication prescriptions: scientific review. JAMA 2002;288: 2868–79
   Google Scholar
• Beardon PH, McGilchrist MM, McKendrick AD, et al. Primary non-compliance with prescribed medication in primary care. BMJ 1993;307: 846–8
   Google Scholar
• Steiner JF, Prochazka AV. The assessment of refill compliance using pharmacy records: methods, validity, and applications. J Clin Epidemiol 1997;50:105–16
   PubMed Web of Science ®Google Scholar